Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Herbal medicine | 1 |
Bispecific antibody | 1 |
Diagnostic radiopharmaceuticals | 1 |
Universal CAR-T | 1 |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. CN |
First Approval Date01 Jan 2000 |
Target- |
Mechanism Fe modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. EU [+3] |
First Approval Date25 Aug 1999 |
Mechanism EGFR antagonists [+1] |
Active Org.- |
Originator Org.- |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Feb 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Irinotecan-eluting beads ( TOP1 ) | Glioma More | Approved |
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells(KK Women's & Children's Hospital Pte Ltd.) ( CD19 x CD22 ) | Acute Lymphoblastic Leukemia More | Phase 2 Clinical |
Anti-CD19 CAR T-cells(KK Women's and Children's Hospital) ( CD19 ) | - | Phase 2 |
Bushen Yijing Pills | Infertility, Male More | Phase 2 |
Deferiprone | Thalassemia More | Clinical |